Physician profile
Roger Keshav
NPI 1942525316
$2,658.18
in general payments reported to CMS, 2019-2025
17 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $72.58 · 2021: $277 · 2022: $498 · 2023: $638 · 2024: $527 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $772.19 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $425.29 | 2021-2025 | |
| Vifor Pharma, INC. | $332.04 | 2022-2025 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $195.60 | 2022-2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $161.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $137.95 | 2019-2025 | |
| Travere Therapeutics, INC. | $126.20 | 2019-2024 | |
| Amgen INC. | $93.11 | 2019-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $78.29 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $78.26 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $75.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Calliditas Therapeutics US INC. | $60.27 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $34.13 | 2022 | |
| Mallinckrodt Enterprises LLC | $30.25 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $27.27 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.72 | 2019 | |
| Lilly USA, LLC | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Keshav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.